MIAMI, Fla. (KFSN) -- Fibromyalgia is often called a mystery illness that causes debilitating pain and fatigue. Most patients take pills to help relieve symptoms. Now, new technology is offering help ...

In the last week, the U.S. FDA has taken two steps to expand treatment options for the millions of patients with fibromyalgia who find little relief from the three approved drugs for the condition.

WOBURN, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has submitted a De Novo request to the U.S. Food and Drug Administration (FDA) for Quell as a ...

Bioelectronic technology company electroCore has completed the acquisition of neurotechnology solution provider NeuroMetrix including its Quell platform. Last December, electroCore signed a definitive ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted De Novo authorization for NeuroMetrix to market its Quell neuromodulation device as an aid ...

Millions of patients with fibromyalgia have battled widespread pain with few effective treatment options for decades. The U.S. FDA has offered reason for hope and better health with four recent ...

The Quell ® neuromodulation device (NeuroMetrix) has received the Food and Drug Administration De Novo authorization for use as an aid in reducing the symptoms of fibromyalgia in adults with high pain ...

SAN DIEGO, Sept. 22, 2017 /PRNewswire/ -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN 100 Class ll medical device is now successfully helping those with the widespread pain associated ...

Fibromyalgia is often called a mystery illness that causes debilitating pain and fatigue. Most patients take pills to help relieve symptoms. In Healthy Living, see how new technology is offering help ...

Quell offers symptom relief to people with fibromyalgia through its transcutaneous electrical nerve stimulation. The technology is housed in a sleeve that’s worn around the upper calf, where ...

WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NURO) today announced U.S. Food and Drug Administration (FDA) De Novo authorization to market the Quell neuromodulation device as an ...